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Abstract: Accumulating evidence linking trimethylamine N-oxide (TMAO) to cardiovascular disease
(CVD) risk has prompted interest in developing therapeutic strategies to reduce its production.
We compared two lifestyle intervention approaches: hypocaloric versus eucaloric diet, combined
with exercise, on TMAO levels in relation to CVD risk factors. Sixteen obese adults (66.1 ± 4.4 years,
BMI (body mass index): 35.9 ± 5.3 kg/m2 , fasting glucose: 106 ± 16 mg/dL, 2-h PPG (postprandial
glucose): 168 ± 37 mg/dL) were randomly assigned to 12 weeks of exercise (5 days/week, 80–85%
HRmax (maximal heart rate)) plus either a hypocaloric (HYPO) (−500 kcal) or a eucaloric (EU) diet.
Outcomes included plasma TMAO, glucose metabolism (oral glucose tolerance test (OGTT) and
euglycemic-hyperinsulinemic clamps for glucose disposal rates (GDR)), exercise capacity (VO2max ,
maximal oxygen consumption), abdominal adiposity (computed tomography scans), cholesterol,
and triglycerides. Results showed that body composition (body weight, subcutaneous adiposity),
insulin sensitivity, VO2max , and cholesterol all improved (p < 0.05). HYPO decreased the percentage
change in TMAO compared to an increase after EU (HYPO: −31 ± 0.4% vs. EU: 32 ± 0.6%, p = 0.04).
Absolute TMAO levels were not impacted (HYPO: p = 0.09 or EU: p = 0.53 group). The change in
TMAO after intervention was inversely correlated with baseline visceral adipose tissue (r = −0.63,
p = 0.009) and GDR (r = 0.58, p = 0.002). A hypocaloric diet and exercise approach appears to be
effective in reducing TMAO. Larger trials are needed to support this observation.
Keywords: trimethylamine N-oxide; obesity; caloric restriction; cardiovascular disease risk factors;
gut microbiome; exercise; lifestyle intervention

1. Introduction
Trimethylamine N-oxide (TMAO) was identified through untargeted metabolomic studies as
a small molecule present in human systemic circulation that promotes cardiovascular disease [1].
More recently, TMAO has been implicated in the pathogenesis of obesity [2], insulin resistance [3–6],
and renal disease [7,8]. Prospective clinical studies have shown that TMAO is predictive of
adverse cardiovascular events, including myocardial infarction, stroke, and death [9]. In addition,
several recent meta-analyses of clinical studies for TMAO all confirm circulating levels predict both
cardiovascular disease and mortality risks, with each 10 µM increase in TMAO level being associated
with an approximate 7.6% increase in relative risk of all-cause mortality [10–12]. A wealth of both
animal model and clinical observation studies suggest that the gut microbiota-dependent TMAO
pathway is an important participant in the development of cardiovascular and metabolic diseases [1].
Nutrients 2019, 11, 179; doi:10.3390/nu11010179
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The biosynthesis of TMAO is unique from traditional cardiovascular disease risk factors, in that
its production is dependent on gut microbial metabolism. The primary precursors of TMAO
are derived from dietary sources of phosphatidylcholine, choline, and L-carnitine. Once in the
digestive tract, gut microbes aid in the catabolism of these compounds resulting in the production of
trimethylamine (TMA) as a metabolic by-product. TMA is rapidly absorbed into the portal circulation
and oxidized by hepatic enzymes, most notably flavin monooxygenase 3 (FMO3), which results in
TMAO production [1,13]. TMAO re-enters the systemic circulation and contributes to the activation of
endogenous macrophage foam cells that participate in the development of atherosclerosis [1,11,14,15].
There is a growing interest in identifying novel therapeutic approaches that reduce TMAO
levels and/or block its production, particularly in obese individuals [2,16] given that adipose tissue
expresses FMO3, the host enzyme responsible for synthesizing TMAO from gut microbiota [2]. While
drug development studies targeting the gut microbial TMAO generating pathway have recently
shown promise in attenuating atherosclerosis [17], and both platelet hyper-responsiveness and in vivo
thrombosis potential in animal models [18], the most effective treatment modality remains unknown [19].
Brief oral courses of poorly absorbed antibiotics have also been shown to suppress TMAO generation in
both mice and humans [1,9,20,21], but chronic antibiotic exposure results in antibiotic resistant microbial
strains colonizing the intestines (and rebound in TMAO levels to pre-antibiotic levels) [1] and potentially
explain the limited success of chronic antibiotics as a cardiovascular disease treatment [22–24]. Lifestyle
modification including exercise and/or diet, on the other hand, is a leading treatment candidate for
impacting TMAO concentrations given the profound effects on cardio-metabolic health. Indeed,
chronic exercise reduces cardiovascular disease risk [25], as well as slows the progression of type
2 diabetes [26] in adults with prediabetes. Interestingly, TMAO levels are increased in diabetics
compared to non-diabetics [2,27]. To date, the effects of supervised exercise training, with or without
dietary caloric restriction, on circulating TMAO levels in obese humans has not yet been reported.
Therefore, this study objective was to assess the impact of a 12-week lifestyle intervention on circulating
TMAO levels in obese adults. Given that a caloric deficit improves obesity-related cardiometabolic
risk factors [28], we sought to compare two different lifestyle approaches differing in energy balance:
(1) exercise combined with a hypocaloric diet, and (2) exercise combined with a eucaloric diet. It was
hypothesized that exercise combined with a hypocaloric diet would be more effective for reducing
TMAO levels than exercise combined with a eucaloric diet. Relationships between TMAO changes
and additional disease risk factors were examined, including body fat, glucose metabolism, and
cardiovascular disease (CVD) risk factors.
2. Materials and Methods
2.1. Study Design
This was a post-hoc analysis of samples collected from previously conducted randomized-controlled
trials investigating the effects of lifestyle interventions on cardiometabolic risk factors [28,29]. We had
pre- and post-intervention plasma samples for sixteen adults with obesity (age: 66.1 ± 4.4 years;
BMI (body mass index): 35.9 ± 5.3 kg/m2 ). The participants had been randomly assigned to either a
12-week eucaloric (EU) diet combined with exercise training, or a hypocaloric (HYPO) diet combined
with exercise training. Anthropometric and metabolic data were collected before and after either the
eucaloric or hypocaloric intervention. During testing phases, participants reported to the Clinical
Research Unit for a 3-day metabolic control period. Activity and diet were closely monitored during
this period. As previously described, a weight-maintenance diet with the following macronutrient
composition (55% carbohydrate, 35% fat, and 10% protein) was provided to participants. Daily caloric
intake was calculated as resting metabolic rate × 1.3 [29]. Metabolic testing procedures were performed
after an approximate 12-h overnight fast.
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2.2. Participants
Participants were weight stable (<2 kg weight change within the past 6 months), sedentary
(<20 min of exercise twice per week), and free of medications known to affect study outcomes. Prior
to study enrollment, participants underwent a medical history, physical examination, oral glucose
tolerance test (OGTT), safety labs, and 12-lead echocardiogram. Participants were recruited from the
local community and came from larger previously published cohorts [28,29]. Previous study protocols
were approved by our Institutional Review Board and all participants provided written informed
consent prior to study participation.
2.3. Lifestyle Intervention
Exercise: The exercise program was equivalent between the eucaloric and hypocaloric groups.
Prior to initiating the exercise program, maximal oxygen consumption (VO2max ) and maximal heart
rate (HRmax ) were measured using an incremental, graded treadmill exercise test. To be considered a
maximal exercise test, participants were required to achieve three of the following four criteria: oxygen
consumption plateau (<150 mL/min), heart rate within 15 beats of age-predicted HRmax , respiratory
exchange ratio >1.15, and/or volitional fatigue. Exercise training occurred at a frequency of 5 days/week,
for 50–60 min in duration, on either a treadmill or cycle ergometer. Initial exercise sessions were
performed at an intensity between 60–65% HRmax . Intensity was gradually increased across sessions so
that by week 4, participants were maintaining an intensity of 80–85% HRmax . VO2max and HRmax were
re-tested in 4-week increments (baseline, 4, 8, and 12 weeks) in order to monitor fitness improvements
and adjust training intensity. All exercise sessions were supervised by an exercise physiologist. Polar
heart rate monitors were used during all exercise sessions to confirm compliance to training intensity.
The last exercise bout was completed approximately 16 h prior to post-testing assessments.
Diet: Participants in the eucaloric group were counseled not to alter their energy intake, while
participants in the hypocaloric group were counseled to reduce daily calories by 500 kcal. In order to
facilitate the caloric deficit, participants met with a nutritionist on a weekly basis. Energy expenditure
was estimated by the Harris–Benedict equation, using an activity factor of 1.3 [30]. Dietary adherence
was monitored via 3-day food recalls, which were completed prior to the intervention, as well as at
weeks 1, 3, 6, 9, and 12. Bodyweight was monitored weekly to confirm compliance.
2.4. Body Composition
Height and weight measurements were taken after approximately 12 h of fasting, and participants
were required to wear a standard hospital gown. Height was measured using a stadiometer and
bodyweight was measured using a calibrated scale. An average of three measurements for both height
and weight are reported. BMI was calculated from these data. Abdominal adiposity was measured
with computerized axial tomography (CT) scans (Picker PQ6000 Scanner; Marconi/Picker Highland
Heights, OH, USA). Cross-sectional images were taken at the L4 region of the abdomen. Regions of
interest included subcutaneous and visceral depots.
2.5. TMAO Measurement
Fasting blood samples were collected in EDTA tubes, processed to isolate plasma, and frozen at
TMAO levels were measured using stable isotope dilution liquid chromatography
with online tandem mass spectrometry using an 8050 triple quadrupole mass spectrometer (Shimadzu
Scientific Instruments, Columbia, MD, USA) as previously described [1,31]. The TMAO assay showed
good inter- and intraday stability (CVs < 7%), accuracy (>98.5%), and stability across freeze–thaw
cycles (intercycle CV < 9%) [31].
−80 ◦ C until analysis.

2.6. Glucose Metabolism
Oral glucose tolerance test (OGTT): Participants consumed a standard drink (75 g glucose). Blood
samples were collected at the following time points: 0, 30, 60, 90, 120, and 180 min. Samples were
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analyzed for glucose and insulin. Total area-under-the-curve (AUC) was a calculated using the
trapezoidal method. Plasma glucose was analyzed using YSI 2300 STAT Plus analyzer (Yellow Springs,
OH, USA). Plasma insulin was analyzed by radioimmunoassay (Millipore, Billerica, MA, USA).
Euglycemic-hyperinsulinemic clamp: Plasma glucose was clamped at 90 mg/dL during
hyperinsulinemia (40 mU/m2 /min−1 ), as previously described [32,33]. A primed-continuous insulin
infusion was carried out over 120 min via catheter placed in the antecubital vein. Glucose (dextrose
20%) was concurrently infused, while the contralateral hand was warmed to 60 ◦ C for the purpose
of arterializing blood. Plasma glucose was assessed every five minutes, and this value was used to
determine subsequent glucose infusion rates. Glucose disposal rate (GDR) during the 90–120 min time
increment of the clamp were reported to determine insulin sensitivity.
2.7. Statistical Analysis
Data are presented as mean ± standard deviation, unless otherwise noted. Data were analyzed
using GraphPad Prism (v7, San Diego, CA, USA). Baseline characteristics between groups were
analyzed using Student’s unpaired t test. Within group changes were analyzed by Student’s paired t
test to test treatment effects. Comparison of between group differences (HYPO: n = 7 vs. EU: n = 9)
was accomplished by repeated measures ANOVA. Secondarily, we compared percent change between
interventions using Student’s unpaired t test. Due to missing data, two post-test data points were
imputed using a group average approach (HYPO: n = 1; EU: n = 1). Relationships between variables
were determined using Pearson’s correlation coefficient. Hierarchical linear regression was used to
statistically control for baseline TMAO levels after statistical significance was detected between percent
change in TMAO and metabolic outcomes (SPSS, IBM v25, Armonk, NY, USA). Data were tested for
normality using Shapiro–Wilk test, and were log transformed when non-normally distributed for
correlation analyses. Significance was accepted at p < 0.05.
3. Results
3.1. Lifestyle Intervention
Participant characteristics are shown in Table 1. There were no baseline differences for any baseline
between eucaloric and hypocaloric groups. The lifestyle intervention significantly improved VO2max in
both eucaloric (pre: 19.7 ± 2.5 vs. post: 22.4 ± 3.1 mL/kg/min; p = 0.005) and hypocaloric (pre: 21.9 ± 2
vs. post: 25.2 ± 2.0 mL/kg/min; p = 0.013) groups. As expected, the magnitude of improvement was
not different between groups (EU: 14.1 ± 11.7% vs. HYPO: 15.5 ± 11.7%, between group: p = 0.81).
Table 1. Participant characteristics before and after lifestyle intervention.
Hypocaloric (n = 7)

Age (years)
Sex (M/F)
Body Weight (kg)
BMI (kg/m2 )
FPG (mg/dL)
2-h PPG (mg/dL)
FPI (µU/mL)
2-h Insulin (µU/mL)
Triglycerides (mg/dL)
Cholesterol (mg/dL)

Eucaloric (n = 9)

Pre

Post

p Value

Pre

Post

p Value

67 ± 5
2/5
100 ± 16
35 ± 5
106 ± 8
160 ± 22
17 ± 7
89 ± 52
161 ± 70
200 ± 19

91 ± 14
32 ± 5
100 ± 10
146 ± 21
13 ± 5
71 ± 61
146 ± 71
181 ± 22

<0.05
<0.05
0.02
0.16
0.05
0.08
0.49
0.04

65 ± 4
3/6
100 ± 19
37 ± 5
106 ± 20
175 ± 45
19 ± 12
104 ± 60
168 ± 51
206 ± 24

94 ± 17
35 ± 5
103 ± 14
154 ± 30
14 ± 6
87 ± 77
134 ± 43
191 ± 30

<0.05
<0.05
0.26
0.16
0.06
0.512
0.009
0.05

Data are displayed as mean ± standard deviation. BMI: body mass index; FPG: fasting plasma glucose; PPG:
postprandial glucose; FPI: fasting plasma insulin; -: statistical test not applicable.

Average kcal/day were reduced by ~500 kcal in the hypocaloric group (pre: 1976.6 ± 273.4 vs.
post: 1403.9 ± 190.1 kcal; p = 0.001), while the eucaloric group remained at maintenance calories (pre:
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3.3. Glucose Metabolism
3.3. Glucose
Metabolism
Oral glucose
tolerance test: Fasting glucose was significantly reduced in the hypocaloric group,
whileOral
the eucaloric
group remained
unchanged,
as shown
in Tablereduced
1. Glucose-AUC
glucose tolerance
test: Fasting
glucose was
significantly
in the hypocaloric
group,
180min responses
while the eucaloric group remained unchanged, as shown in Table 1. Glucose-AUC180min responses
trended towards a reduction in the hypocaloric group (pre: 24,555 ± 2549 vs. post: 21,608 ± 2352 mg/dL
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trended towards a reduction in the hypocaloric group (pre: 24,555 ± 2549 vs. post: 21,608 ± 2352
mg/dL × 180 min; p = 0.071) and remained unchanged in the eucaloric group (pre: 25,821 ± 6127
vs. post: 24,064 ± 3696 mg/dL × 180 min; p = 0.173). Fasting insulin trended toward a reduction
in both groups, as shown in Table 1. Insulin AUC180min responses tended to decrease in both the
hypocaloric (pre: 10,432 ± 4577 vs. post: 6,469 ± 1870 µU/mL × 180 min; p = 0.079) and eucaloric (pre:
15,162 ± 9912 vs. post: 11,520 ± 7236 µU/mL × 180 min; p = 0.075) groups, although this effect was not
statistically significant.
Euglycemic-hyperinsulinemic clamp: Peripheral insulin sensitivity, as assessed by glucose disposal
rates, significantly improved in both the hypocaloric and eucaloric groups, as shown in Figure 2A.
The magnitude of improvement was not different between groups (HYPO: 83.6% vs. EU: 59.6%;
p = 0.41).

Figure 2.
(A) Individual glucose disposal rates during 90–120 min time increment of
euglycemic-hyperinsulinemic clamp before and after the 12-wk lifestyle intervention, which increased
in both hypocaloric and eucaloric groups. Group average denoted by horizontal line, with standard
deviation bars. (B) Individual computed tomography-measured subcutaneous fat depots before and
after 12-wk lifestyle intervention, which decreased in both hypocaloric and eucaloric groups. Group
average denoted by horizontal line, with standard deviation bars. * indicates p < 0.05.

3.4. Abdominal Adiposity
Subcutaneous abdominal fat depot significantly decreased in both the hypocaloric and eucaloric
groups, as shown in Figure 2B. The hypocaloric group experienced a larger percent reduction than the
eucaloric group (HYPO: −27% vs. EU: −10%; p = 0.013).
The visceral abdominal fat depot was significantly decreased in the eucaloric group (pre: 174.9 ± 118
vs. post: 138.9 ± 98 cm2 ; p = 0.025), while the hypocaloric group was unchanged (pre: 255.7 ± 96 vs.
post: 232 ± 67 cm2 ; p = 0.434). The relative decrease was not different between groups (HYPO: −6.1%
vs. −16.3%; p = 0.156).
3.5. Lipid Profile
Cholesterol was significantly reduced in the hypocaloric group, while the eucaloric group trended
towards a significant reduction, as shown in Table 1. The relative decrease was not different between
groups (HYPO: 9.2% vs. EU: 7.5%; p = 0.752). In addition, triglycerides were significantly reduced in
the eucaloric but not hypocaloric group, as shown in Table 1. The relative decrease was not different
between groups (HYPO: −5.7% vs. EU: −19.6%; p = 0.233).
3.6. Correlation Analysis
Baseline absolute VO2max was significantly correlated with baseline levels of TMAO, as shown in
Figure 3A, (r = 0.67, p = 0.004). Change in TMAO after lifestyle intervention was inversely correlated
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to a caloric restriction protocol is unknown, and larger trials with rigorous dietary control will be
needed to address these issues.
TMAO production is dependent on gut microbial metabolism creating novel opportunities to
therapeutically target the microbiome. It is well accepted that environmental exposures such as
exercise and diet contribute to the composition of the gut microbiome. While exercise has been
shown to alter gut microbiome distribution and diversity [36,37], the current study showed that 12
weeks of supervised exercise in the eucaloric diet arm did not significantly reduce TMAO levels. It is
notable that prior studies have suggested that inter-individual variations in TMAO level responses
to animal source foods depends upon the starting microbial composition [38]. The lack of effect of
exercise on TMAO levels, might similarly be explained by inter-individual variation in gut microbial
community composition [38]. Although baseline TMAO differences were not observed between groups
(p = 0.26), we cannot rule out that a ‘bottom effect’ may be limiting the magnitude of decrease within
the eucaloric arm. Systemic monitoring of TMAO levels during lifestyle intervention might permit a
more personalized approach toward lifestyle intervention with improved reduction in cardiovascular
and metabolic risks, though further studies with hard outcomes are needed in this area. Although
exercise alone did not significantly reduce TMAO, it is important to note that numerous alternative
beneficial effects occurred in the eucaloric arm of the study, including reductions in body weight,
abdominal adiposity, and as well as improvements in peripheral insulin sensitivity, triglycerides, and
cholesterol. Thus, exercise remains an effective treatment against cardio-metabolic diseases and future
studies should continue to explore the impact of exercise on the gut microbiome in order to assess the
significance of TMAO metabolism.
A noteworthy observation is that both intervention approaches led to comparable improvements
in several health-related outcomes, while the direction of TMAO responses differed between the
groups. Specifically, both hypocaloric and eucaloric groups experienced reductions in body weight and
abdominal adiposity, as well as improvements in aerobic capacity and peripheral insulin sensitivity.
Consistent with our findings, a study of 220 subjects undergoing lifestyle intervention showed
improvements in several cardiovascular risk factors, while TMAO levels were unchanged [35].
In addition, a secondary analysis of the PREDIMED trial reported an inverse relationship between
TMAO levels and type 2 diabetes risk after one year of dietary intervention in 694 subjects [39].
Interestingly, our correlation analysis is consistent with this later report in that we show people
who have less visceral fat and who are more insulin sensitive have smaller reductions in TMAO
post-treatment. However, we collectively see that on average our treatments reduce cardiovascular
disease risk factors in both hypocaloric and eucaloric exercise interventions. Taken together, these
findings suggest that improvements in cardio-metabolic health can be realized in the presence or
absence of TMAO reductions based on the subject population. Given the role of TMAO in atherosclerotic
development, it is possible that stronger relationships between TMAO after lifestyle intervention and
vascular outcomes could be seen in patients with diagnosed cardiovascular or renal disease.
The current study is not without limitations that warrant mention. This was a post-hoc analysis in
which we analyzed a sample of participants from previously conducted randomized controlled trials.
We acknowledge that the sample size was modest. However, given the novelty of our primary outcome
(human TMAO concentrations) it was not possible to complete a priori power calculations to guide
sample size decisions. We observed significant differences between interventional approaches only
when data were expressed as percent change. This could be partially attributed to large inter-individual
variability in TMAO responses. Similarly, there is some evidence that factors such as sex and FMO3
genetic variants can influence TMAO levels [13,40]. It is notable that recent meta-analyses of clinical
TMAO studies indicate that per 10 uM change (increase) in TMAO, there is a corresponding 7.6%
increase in overall mortality risk [10]. Whether those that achieved TMAO reduction with the present
interventions benefitted will require long-term outcome trials. Another limitation of the present study
is precise measurements of known dietary precursors of TMAO were not performed, and such analyses
could possibly have strengthened our conclusions. Given the study design, it is not possible to assess
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the temporality of TMAO changes, so the acute versus chronic effects of lifestyle-induced changes on
TMAO remains unknown. Nonetheless, these novel data provide insight that can be used to inform
the development of future studies testing the effects of lifestyle modification on TMAO in humans.
Through this post-hoc analysis, we found that diet-induced caloric restriction combined with
supervised exercise may be more effective for reducing circulating TMAO, compared to exercise
combined with a eucaloric diet. This may suggest that TMAO levels are more amenable to change
through dietary-induced caloric restriction versus an exercise effect alone. However, we observed
that health improvements occurred in the absence of a significant TMAO reduction, suggesting that
exercise acts, in part, through the TMAO-independent pathway in obese, insulin-resistant adults.
Randomized controlled trials with larger samples sizes will be needed to confirm our findings. Future
studies should also aim to tease out the impact of negative energy balance versus reductions in absolute
levels of TMAO in dietary precursors for promoting beneficial changes in TMAO levels and reducing
cardio-metabolic disease risk.
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